vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Dynatrace, Inc. (DT). Click either name above to swap in a different company.
Dynatrace, Inc. is the larger business by last-quarter revenue ($515.5M vs $284.0M, roughly 1.8× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 7.8%, a 88.6% gap on every dollar of revenue. On growth, Dynatrace, Inc. posted the faster year-over-year revenue change (18.2% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 16.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Dynatrace, Inc. is an American multinational technology company that provides an AI-powered observability platform. Their software is used to monitor, analyze, and optimize application performance, software development, cyber security practices, IT infrastructure, and user experience.
ACAD vs DT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $515.5M |
| Net Profit | $273.6M | $40.1M |
| Gross Margin | 90.8% | 81.4% |
| Operating Margin | 6.1% | 14.1% |
| Net Margin | 96.3% | 7.8% |
| Revenue YoY | 9.4% | 18.2% |
| Net Profit YoY | 90.3% | -88.9% |
| EPS (diluted) | $1.61 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $515.5M | ||
| Q3 25 | $278.6M | $493.8M | ||
| Q2 25 | $264.6M | $477.3M | ||
| Q1 25 | $244.3M | $445.2M | ||
| Q4 24 | $259.6M | $436.2M | ||
| Q3 24 | $250.4M | $418.1M | ||
| Q2 24 | $242.0M | $399.2M | ||
| Q1 24 | $205.8M | $380.8M |
| Q4 25 | $273.6M | $40.1M | ||
| Q3 25 | $71.8M | $57.2M | ||
| Q2 25 | $26.7M | $48.0M | ||
| Q1 25 | $19.0M | $39.3M | ||
| Q4 24 | $143.7M | $361.8M | ||
| Q3 24 | $32.8M | $44.0M | ||
| Q2 24 | $33.4M | $38.6M | ||
| Q1 24 | $16.6M | $37.9M |
| Q4 25 | 90.8% | 81.4% | ||
| Q3 25 | 92.2% | 81.8% | ||
| Q2 25 | 92.2% | 82.1% | ||
| Q1 25 | 91.7% | 80.9% | ||
| Q4 24 | 91.6% | 81.1% | ||
| Q3 24 | 92.5% | 81.4% | ||
| Q2 24 | 92.5% | 81.3% | ||
| Q1 24 | 88.8% | 81.1% |
| Q4 25 | 6.1% | 14.1% | ||
| Q3 25 | 12.8% | 14.8% | ||
| Q2 25 | 12.2% | 13.1% | ||
| Q1 25 | 7.9% | 9.6% | ||
| Q4 24 | 59.1% | 10.9% | ||
| Q3 24 | 12.6% | 11.2% | ||
| Q2 24 | 12.6% | 10.5% | ||
| Q1 24 | 7.4% | 6.1% |
| Q4 25 | 96.3% | 7.8% | ||
| Q3 25 | 25.8% | 11.6% | ||
| Q2 25 | 10.1% | 10.0% | ||
| Q1 25 | 7.8% | 8.8% | ||
| Q4 24 | 55.4% | 82.9% | ||
| Q3 24 | 13.1% | 10.5% | ||
| Q2 24 | 13.8% | 9.7% | ||
| Q1 24 | 8.0% | 10.0% |
| Q4 25 | $1.61 | $0.13 | ||
| Q3 25 | $0.42 | $0.19 | ||
| Q2 25 | $0.16 | $0.16 | ||
| Q1 25 | $0.11 | $0.12 | ||
| Q4 24 | $0.86 | $1.19 | ||
| Q3 24 | $0.20 | $0.15 | ||
| Q2 24 | $0.20 | $0.13 | ||
| Q1 24 | $0.10 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $1.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $2.7B |
| Total Assets | $1.6B | $4.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $1.2B | ||
| Q3 25 | $258.0M | $1.3B | ||
| Q2 25 | $253.6M | $1.3B | ||
| Q1 25 | $217.7M | $1.1B | ||
| Q4 24 | $319.6M | $1.0B | ||
| Q3 24 | $155.1M | $1.0B | ||
| Q2 24 | $177.1M | $1.0B | ||
| Q1 24 | $204.7M | $836.9M |
| Q4 25 | $1.2B | $2.7B | ||
| Q3 25 | $917.3M | $2.8B | ||
| Q2 25 | $822.4M | $2.7B | ||
| Q1 25 | $765.2M | $2.6B | ||
| Q4 24 | $732.8M | $2.6B | ||
| Q3 24 | $577.2M | $2.1B | ||
| Q2 24 | $516.7M | $2.1B | ||
| Q1 24 | $464.0M | $2.0B |
| Q4 25 | $1.6B | $4.1B | ||
| Q3 25 | $1.3B | $4.1B | ||
| Q2 25 | $1.2B | $4.1B | ||
| Q1 25 | $1.1B | $4.1B | ||
| Q4 24 | $1.2B | $3.7B | ||
| Q3 24 | $976.9M | $3.3B | ||
| Q2 24 | $914.1M | $3.3B | ||
| Q1 24 | $855.1M | $3.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $33.8M |
| Free Cash FlowOCF − Capex | — | $27.2M |
| FCF MarginFCF / Revenue | — | 5.3% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | -0.18× | 0.84× |
| TTM Free Cash FlowTrailing 4 quarters | — | $465.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $33.8M | ||
| Q3 25 | $74.3M | $32.0M | ||
| Q2 25 | $64.0M | $269.7M | ||
| Q1 25 | $20.3M | $162.8M | ||
| Q4 24 | $40.4M | $42.2M | ||
| Q3 24 | $63.2M | $23.6M | ||
| Q2 24 | $25.0M | $230.7M | ||
| Q1 24 | $29.1M | $131.7M |
| Q4 25 | — | $27.2M | ||
| Q3 25 | $73.9M | $27.8M | ||
| Q2 25 | — | $262.2M | ||
| Q1 25 | — | $148.2M | ||
| Q4 24 | — | $37.6M | ||
| Q3 24 | $63.2M | $20.1M | ||
| Q2 24 | — | $227.4M | ||
| Q1 24 | — | $121.9M |
| Q4 25 | — | 5.3% | ||
| Q3 25 | 26.5% | 5.6% | ||
| Q2 25 | — | 54.9% | ||
| Q1 25 | — | 33.3% | ||
| Q4 24 | — | 8.6% | ||
| Q3 24 | 25.2% | 4.8% | ||
| Q2 24 | — | 57.0% | ||
| Q1 24 | — | 32.0% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | -0.18× | 0.84× | ||
| Q3 25 | 1.03× | 0.56× | ||
| Q2 25 | 2.40× | 5.62× | ||
| Q1 25 | 1.07× | 4.14× | ||
| Q4 24 | 0.28× | 0.12× | ||
| Q3 24 | 1.93× | 0.54× | ||
| Q2 24 | 0.75× | 5.97× | ||
| Q1 24 | 1.76× | 3.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
DT
| Subscription And Circulation | $493.4M | 96% |
| Services | $22.1M | 4% |
